SAFETY DATA SHEET



1. Identification

Product identifier Naratriptan Tablets USP

Other means of identification

Product code 1mg white to off-white, round biconvex tablet, with product identification "54" printed on one side,

and "227" on the other., 2.5mg Tablet, debossed with product identification "54 351" on one side,

and plain on the other

Recommended use Indicated for the acute treatment of migraine with or without aura in adults

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Company name West-Ward Pharmaceuticals Corporation

Address 1809 Wilson Road

Columbus, Ohio 43228

Telephone (614) 276-4000 Emergency phone number (614) 276-4000

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.
Signal word Warning

Hazard statement This is a pharmaceutical product designed to be prescribed by a licensed health care

professional. Should any person while using this product observe any adverse health effects, they

should seek medical treatment.

Precautionary statement

Prevention Observe good industrial hygiene practices.

Response Wash hands after handling.

Storage Store away from incompatible materials. Store at 20 - 25 °C (68 - 77°F).

Disposal Incineration of waste at an approved USEPA incinerator is recommended.

Hazard(s) not otherwise

classified (HNOC)

None known.

3. Composition/information on ingredients

Substances

Chemical name	Common name and synonyms	CAS number	%
Naratriptan hydrochloride		143388-64-1	1mg - 2.5mg

4. First-aid measures

Inhalation If dust from the material is inhaled, remove the affected person immediately to fresh air. Call a

physician if symptoms develop or persist.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. Get medical attention if symptoms occur. If ingestion of a large amount does occur,

call a poison control center immediately.

Most important symptoms/effects, acute and delayed

Most common side effects are paresthesias, nausea, dizziness, drowsiness, malaise/fatigue, and throat/neck symptoms.

Indication of immediate medical attention and special treatment needed

No specific antidotes are recommended. Provide general supportive measures and treat symptomatically.

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

and precautions for firefighters Fire fighting

Use water spray to cool unopened containers.

equipment/instructions
Specific methods

media

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Wear appropriate personal protective equipment (See Section

ę

Methods and materials for containment and cleaning up

Sweep up and place into a proper container for disposal. Minimize dust generation and accumulation. Collect dust using a vacuum cleaner equipped with HEPA filter. Following product recovery, flush area with water. Incineration of waste at an approved USEPA incinerator is recommended.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Avoid breathing dust. Wash hands thoroughly after

handling.

Conditions for safe storage, including any incompatibilities

Store at controlled room temperature at 20–25 °C (68-77°F). Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)

Components	Туре	Value	Form
Dust	PEL	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
US. OSHA Table Z-3 (29	CFR 1910.1000)		
Components	Туре	Value	Form
Dust	TWA	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
		50 mppcf	Total dust.
		15 mppcf	Respirable fraction.
US. ACGIH Threshold L	imit Values		
Components	Туре	Value	Form
Dust	TWA	3 mg/m3	Respirable particles.
		10 mg/m3	Inhalable particles.
ogical limit values	No biological exposure limits noted for the ingredient(s).		

Appropriate engineering

Ventilation should be matched to conditions.

controls

Individual protection measures, such as personal protective equipment

Eye/face protection

None required for consumer use. In laboratory, medical or industrial settings, safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting. Contact a health and safety professional for specific information.

Skin protection

Hand protection For consumer use, no unusual precautions are necessary.

Other

None required for consumer use. In laboratory, medical or industrial settings, gloves and lab coats are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary. Contact a health and safety professional for

specific information.

Respiratory protection None required for consumer use. Respirators may be required for certain laboratory and

manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a

health and safety professional or manufacturer for specific information.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

9. Physical and chemical properties

Appearance White tablet.

Solid. **Physical state Form** Tablet. Color White.

Odor Not available. **Odor threshold** Not available. Not available. Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point **Evaporation rate** Not available. Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

Not available.

Explosive limit - lower (%) Not available. Explosive limit - upper (%) Not available. Vapor pressure Not available. Not available.

Vapor density Not available. Relative density

Solubility(ies)

Solubility (water) Soluble

Partition coefficient (n-octanol/water)

Not available.

Not available. **Auto-ignition temperature Decomposition temperature** Not available.

Naratriptan Tablets USP SDS US

926288 Version #: 01 Revision date: -Issue date: 08-May-2015 Viscosity Not available.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

Inhalation Not expected to be hazardous in final pharmaceutical form. Mechanical processing may generate

dust. Inhalation of dusts may cause respiratory irritation.

Skin contactNot expected to be hazardous in final pharmaceutical form. Mechanical processing may generate

dust. Dust or powder may irritate the skin.

Eye contact Not expected to be hazardous in final pharmaceutical form. Mechanical processing may generate

dust. Dust may irritate the eyes.

Ingestion Ingestion may cause irritation and malaise.

Symptoms related to the physical, chemical and toxicological characteristics

Most common side effects are paresthesias, nausea, dizziness, drowsiness, malaise/fatigue, and

throat/neck symptoms.

Information on toxicological effects

Acute toxicity May be harmful if swallowed in large quantities.

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Serious eye damage/eye

irritation

Dust may irritate the eyes.

Respiratory or skin sensitization

Respiratory sensitization Not a respiratory sensitizer.

Skin sensitization This product is not expected to cause skin sensitization.

Germ cell mutagenicity This product is not expected to be mutagenic.

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicityThis product is not expected to cause reproductive or developmental effects.

Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking

into account the importance of the drug to the mother.

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazardDue to the physical form of the product it is not an aspiration hazard.

Further information See package insert.

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous. **Persistence and degradability** No data is available on the degradability of this product.

Bioaccumulative potential No data available.

Mobility in soil Product components are soluble in water and will slowly dissolve and disperse.

Other adverse effects None.

13. Disposal considerations

Disposal instructionsCollect and reclaim or dispose in sealed containers at licensed waste disposal site.

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable.

15. Regulatory information

US federal regulations

This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use.

OSHA GHS: GHS symbols in consumer packaged form are not required per OSHA 29 CFR 1910.1200(b)(5) and OSHA 29 CFR 1910.1200(b)(5)(iii).

Over-the-counter drugs in their solid final form (i.e. tablets or pills) are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limits may be surpassed, they can be considered hazardous.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

No

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act Not regulated.

(SDWA)
Not listed.

US state regulations

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

Not listed.

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)*CanadaDomestic Substances List (DSL)NoUnited States & Puerto RicoToxic Substances Control Act (TSCA) InventoryNo

16. Other information, including date of preparation or last revision

Issue date 08-May-2015

Revision date - 01

References 1) Naratriptan Tablets USP, Package Insert, West-Ward Pharmaceuticals Corporation, Columbus, Ohio.

- 2) PDR Physicians Desk Reference.
- 3) Ariel Webinsight. Regulatory and ChemExpert Database.

Disclaimer West-Ward Pharmaceuticals Corporation cannot anticipate all conditions under which this information and

its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently

6/6

available.

Naratriptan Tablets USP SDS US

926288 Version #: 01 Revision date: - Issue date: 08-May-2015

^{*}A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).